About SSI Diagnostica Group
SSI Diagnostica Group is a globally active specialty diagnostics company focusing on the development and manufacturing of rapid tests for gastrointestinal, respiratory, and bloodborne diseases. In addition, it serves as a trusted partner to vaccine manufacturers worldwide by supplying high-quality antisera essential to their R&D and quality control processes.
The Journey
Commercialization of a formerly state-owned entity and succesfully establishing a global powerhouse in specialty infectious disease diagnostics.
Key Highlights:
- Carve-out of state-owned entity and building a new management team
- Developing and investing in a new R&D and commercial strategy focusing on rapid tests for infectious disease diagnostics and reagents for vaccine quality control
- Expansion into the US and other geographies with value-accretive M&A:
- CTK Biotech (2020): expanding into bloodborne and tropical disease diagnostics targeted at emerging markets, doubling size of business
- Techlab (2022): adding broad complementary portfolio of FDA approved gastrointestinal tests and gaining strong direct sales and distribution footprint in the US
- Gulf Coast Scientific (2025): enhancing gastrointestinal diagnostics portfolio by adding complementary H. pylori breath test
- Execution of a disciplined organic and inorganic growth strategy, ultimately establishing a world-leading position across several niche infectious disease areas (incl. C.Diff, H.Pylori, Pneumoccus and Dengue)
- Since entry in 2016, the Company has grown from ~80 to ~600 employees globally and from c.€20m to over €110m in sales
Rasmus Molander
["Entry","Year 1","Year 2","Year 3","Year 4","Year 5","Year 6","Year 7","Year 8","Year 9"]
1
Financial Development
5x
20% annualized growth
